Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Tuberculosis

  Free Subscription


Articles published in Eur Respir J

Retrieve available abstracts of 146 articles:
HTML format
Text format



Single Articles


    November 2018
  1. FROBERG G, Jansson L, Bruchfeld J
    Treatment of latent tuberculosis with 12-weeks isoniazid/rifapentine in clinical practice.
    Eur Respir J. 2018 Nov 8. pii: 13993003.01128-2018.
    PubMed     Text format    


    October 2018
  2. DALE KD, Trauer JM, Dodd PJ, Houben RMGJ, et al
    Estimating the prevalence of latent tuberculosis in a low incidence setting: Australia.
    Eur Respir J. 2018 Oct 25. pii: 13993003.01218-2018.
    PubMed     Text format     Abstract available


  3. NDJEKA N, Schnippel K, Master I, Meintjes G, et al
    High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
    Eur Respir J. 2018 Oct 25. pii: 13993003.01528-2018.
    PubMed     Text format     Abstract available


  4. GOLETTI D, Lindestam Arlehamn CS, Scriba TJ, Anthony R, et al
    Can we predict tuberculosis cure? Current tools available.
    Eur Respir J. 2018 Oct 25. pii: 13993003.01089-2018.
    PubMed     Text format     Abstract available


  5. GAO L, Zhang H, Xin H, Liu J, et al
    Short-course Regimens of Rifapentine plus Isoniazid to Treat Latent Tuberculosis Infection in Older Chinese: a Randomised Controlled Study.
    Eur Respir J. 2018 Oct 25. pii: 13993003.01470-2018.
    PubMed     Text format     Abstract available


  6. COLLIN SM, de Vries G, Lonnroth K, Migliori GB, et al
    Tuberculosis in the European Union and European Economic Area: a survey of national tuberculosis programmes.
    Eur Respir J. 2018 Oct 11. pii: 13993003.01449-2018.
    PubMed     Text format     Abstract available


  7. LAW S, Daftary A, O'Donnell M, Padayatchi N, et al
    Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review.
    Eur Respir J. 2018 Oct 11. pii: 13993003.01030-2018.
    PubMed     Text format     Abstract available


  8. GANDHI NR, Brust JCM, Shah NS
    A new era for treatment of drug-resistant tuberculosis.
    Eur Respir J. 2018;52.
    PubMed     Text format    


  9. RUHWALD M, Diel R
    Escaping the Plato's cave of latent tuberculosis testing: a path for developers of predictive tests for risk of tuberculosis.
    Eur Respir J. 2018;52.
    PubMed     Text format    


    September 2018
  10. MIGLIORI GB, Sotgiu G, Rosales-Klintz S, van der Werf MJ, et al
    European Union standard for tuberculosis care on treatment of multidrug-resistant tuberculosis following publication of the new World Health Organization recommendations.
    Eur Respir J. 2018 Sep 12. pii: 13993003.01617-2018.
    PubMed     Text format    


  11. CABIBBE AM, Walker TM, Niemann S, Cirillo DM, et al
    Whole Genome Sequencing of Mycobacterium tuberculosis.
    Eur Respir J. 2018 Sep 12. pii: 13993003.01163-2018.
    PubMed     Text format     Abstract available


    August 2018
  12. NSENGIYUMVA NP, Mappin-Kasirer B, Oxlade O, Bastos M, et al
    Evaluating the potential costs and impact of digital health technologies for tuberculosis treatment support.
    Eur Respir J. 2018 Aug 30. pii: 13993003.01363-2018.
    PubMed     Text format     Abstract available


  13. KIK SV, Schumacher S, Maria Cirillo D, Churchyard G, et al
    An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease.
    Eur Respir J. 2018 Aug 23. pii: 13993003.00946-2018.
    PubMed     Text format     Abstract available


  14. AULD SC, Sarita Shah N, Mathema B, Brown TS, et al
    XDR tuberculosis in South Africa: genomic evidence supporting transmission in communities.
    Eur Respir J. 2018 Aug 16. pii: 13993003.00246-2018.
    PubMed     Text format     Abstract available


  15. UZORKA JW, Delfos NM, Witte AMC, Scheper H, et al
    Tuberculosis after a borderline QuantiFERON result during screening before infliximab.
    Eur Respir J. 2018;52.
    PubMed     Text format    


    June 2018
  16. PONTALI E, Sotgiu G, Tiberi S, Tadolini M, et al
    Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.
    Eur Respir J. 2018 Jun 14. pii: 13993003.00934-2018.
    PubMed     Text format    


  17. GUGLIELMETTI L, Tiberi S, Burman M, Kunst H, et al
    QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: A Tuberculosis Network European Trialsgroup (TBnet) study.
    Eur Respir J. 2018 Jun 7. pii: 13993003.00537-2018.
    PubMed     Text format    


    May 2018
  18. DOBLER CC, Fox GJ, Douglas P, Viney KA, et al
    Screening for tuberculosis in migrants and visitors from high incidence settings: present and future perspectives.
    Eur Respir J. 2018 May 24. pii: 13993003.00591-2018.
    PubMed     Text format     Abstract available


  19. ASSEFA Y, Assefa Y, Woldeyohannes S, Hamada Y, et al
    Three-month daily Rifampicin and Isoniazid compared to six or nine-month Isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review.
    Eur Respir J. 2018 May 10. pii: 13993003.00395-2018.
    PubMed     Text format    


  20. MOHR E, Hughes J, Reuter A, Trivino Duran L, et al
    Delamanid for Rifampicin-Resistant Tuberculosis: A Retrospective Study from South Africa.
    Eur Respir J. 2018 May 3. pii: 13993003.00017-2018.
    PubMed     Text format     Abstract available


  21. MUSTAZZOLU A, Borroni E, Maria Cirillo D, Giannoni F, et al
    Trend of rifampicin resistant, MDR and XDR tuberculosis in Italy, 2009-2016.
    Eur Respir J. 2018 May 3. pii: 13993003.00070-2018.
    PubMed     Text format    


  22. ABUBAKAR I, Matteelli A, de Vries G, Zenner D, et al
    Towards tackling tuberculosis in vulnerable groups in the European Union: the E-DETECT TB consortium.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  23. VILLANUEVA P, Neth O, Ritz N, Tebruegge M, et al
    Use of Xpert MTB/RIF Ultra assays among paediatric tuberculosis experts in Europe.
    Eur Respir J. 2018;51.
    PubMed     Text format    



  24. "Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey." Dodge R. Lim, Anna S. Dean, Mary Rosary Taguinod-Santiago, Angeli Borbe-Reyes, Andrea Maurizio Cabibbe, Matteo Zignol, Ra
    Eur Respir J. 2018;51.
    PubMed     Text format    


    April 2018
  25. OLAYANJU O, Limberis J, Esmail A, Oelofse S, et al
    LONG TERM BEDAQUILINE-RELATED TREATMENT OUTCOMES IN PATIENTS WITH EXTENSIVELY DRUG RESISTANT TUBERCULOSIS FROM SOUTH AFRICA.
    Eur Respir J. 2018 Apr 26. pii: 13993003.00544-2018.
    PubMed     Text format    


  26. MIGLIORI GB, Sotgiu G, Rosales-Klintz S, Centis R, et al
    ERS/ECDC Statement: European Union Standards for Tuberculosis Care - 2017 update.
    Eur Respir J. 2018 Apr 20. pii: 13993003.02678-2017.
    PubMed     Text format     Abstract available


  27. CABIBBE AM, Trovato A, De Filippo MR, Ghodousi A, et al
    Countrywide implementation of whole genome sequencing: an opportunity to improve tuberculosis management, surveillance and contact tracing in low incidence countries.
    Eur Respir J. 2018 Apr 12. pii: 13993003.00387-2018.
    PubMed     Text format    


  28. CHANG KC, Chung-Ching Leung E, Law WS, Leung WM, et al
    Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong.
    Eur Respir J. 2018 Apr 12. pii: 13993003.00159-2018.
    PubMed     Text format    


    March 2018
  29. LYLES G, Ogarkov O, Zhdanova S, Peloquin CA, et al
    Pharmacokinetics of tuberculosis drugs in HIV infected patients from Irkutsk, Russian Federation: redefining drug activity.
    Eur Respir J. 2018 Mar 29. pii: 13993003.00109-2018.
    PubMed     Text format    


  30. JAFARI C, Olaru ID, Daduna F, Ernst M, et al
    Rapid diagnosis of pulmonary tuberculosis by combined molecular and immunological methods.
    Eur Respir J. 2018 Mar 29. pii: 13993003.02189-2017.
    PubMed     Text format     Abstract available


  31. LIM DR, Dean AS, Taguinod-Santiago MR, Borbe-Reyes A, et al
    Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey.
    Eur Respir J. 2018 Mar 1. pii: 13993003.02571-2017.
    PubMed     Text format    


  32. KIM CT, Kim TO, Shin HJ, Ko YC, et al
    Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
    Eur Respir J. 2018;51.
    PubMed     Text format     Abstract available


  33. SAUNDERS MJ, Tovar MA, Datta S, Evans BEW, et al
    Pragmatic tuberculosis prevention policies for primary care in low- and middle-income countries.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  34. RUDGARD WE, das Chagas NS, Gayoso R, Barreto ML, et al
    Uptake of governmental social protection and financial hardship during drug-resistant tuberculosis treatment in Rio de Janeiro, Brazil.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  35. MUSVOSVI M, Duffy D, Filander E, Africa H, et al
    T-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translation.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  36. GILPIN C, Korobitsyn A, Migliori GB, Raviglione MC, et al
    The World Health Organization standards for tuberculosis care and management.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  37. DE VRIES G, van den Hof S, Op de Coul E, van Crevel R, et al
    Closing the gap in surveillance of tuberculosis and HIV co-infection, and the need for clinician-public health alliances.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  38. MUNOZ-TORRICO M, Salazar MA, Millan MJM, Martinez Orozco JA, et al
    Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  39. TIBERI S, Payen MC, Sotgiu G, D'Ambrosio L, et al
    Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  40. HALLEUX CM, Falzon D, Merle C, Jaramillo E, et al
    The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis.
    Eur Respir J. 2018;51.
    PubMed     Text format    


    February 2018
  41. SULIS G, Agliati A, Pinsi G, Bozzola G, et al
    Xpert MTB/RIF as add-on test to microscopy in a low tuberculosis incidence setting.
    Eur Respir J. 2018 Feb 8. pii: 13993003.02345-2017.
    PubMed     Text format    


  42. AKKERMAN OW, Grasmeijer F, de Lange WCM, Kerstjens HAM, et al
    Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.
    Eur Respir J. 2018 Feb 1. pii: 13993003.02490-2017.
    PubMed     Text format    


  43. CHIANG CY, Trebucq A
    Tuberculosis re-treatment after exclusion of rifampicin resistance.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  44. KEMPKER RR, Heinrichs MT, Nikolaishvili K, Sabulua I, et al
    A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  45. JOHNSTON JC, van der Kop ML, Smillie K, Ogilvie G, et al
    The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial.
    Eur Respir J. 2018;51.
    PubMed     Text format     Abstract available


  46. GARCIA-BASTEIRO AL, Schaaf HS, Diel R, Migliori GB, et al
    Adolescents and young adults: a neglected population group for tuberculosis surveillance.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  47. ALVAREZ-URIA G, Midde M
    Sex differences and factors influencing the duration of the QT interval in patients on anti-tuberculosis therapy.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  48. SNOW KJ, Sismanidis C, Denholm J, Sawyer SM, et al
    The incidence of tuberculosis among adolescents and young adults: a global estimate.
    Eur Respir J. 2018;51.
    PubMed     Text format     Abstract available


  49. HEYCKENDORF J, van Leth F, Kalsdorf B, Olaru ID, et al
    Relapse-free cure from multidrug-resistant tuberculosis in Germany.
    Eur Respir J. 2018;51.
    PubMed     Text format    


    January 2018
  50. HEYSELL SK, Ahmed S, Rahman MT, Akhanda MW, et al
    Hearing loss with Kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh.
    Eur Respir J. 2018 Jan 18. pii: 13993003.01778-2017.
    PubMed     Text format    


  51. ACUNA-VILLAORDUNA C, Jones-Lopez EC, Fregona G, Marques-Rodrigues P, et al
    Intensity of exposure to pulmonary tuberculosis determines risk of tuberculosis infection and disease.
    Eur Respir J. 2018;51.
    PubMed     Text format     Abstract available


  52. NGWATU BK, Nsengiyumva NP, Oxlade O, Mappin-Kasirer B, et al
    The impact of digital health technologies on tuberculosis treatment: a systematic review.
    Eur Respir J. 2018;51.
    PubMed     Text format     Abstract available


  53. LOUTET MG, Burman M, Jayasekera N, Trathen D, et al
    National roll-out of latent tuberculosis testing and treatment for new migrants in England: a retrospective evaluation in a high-incidence area.
    Eur Respir J. 2018;51.
    PubMed     Text format     Abstract available


  54. AL YAQUOBI F, Al-Abri S, Al-Abri B, Al-Abaidani I, et al
    Tuberculosis elimination: a dream or a reality? The case of Oman.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  55. VAN DEN ELSEN SHJ, Akkerman OW, Huisman JR, Touw DJ, et al
    Lack of penetration of amikacin into saliva of tuberculosis patients.
    Eur Respir J. 2018;51.
    PubMed     Text format    


  56. PADRAO E, Oliveira O, Felgueiras O, Gaio AR, et al
    Tuberculosis and tobacco: is there any epidemiological association?
    Eur Respir J. 2018;51.
    PubMed     Text format    


    December 2017
  57. CHE Y, Song Q, Yang T, Ping G, et al
    Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  58. CABIBBE AM, Sotgiu G, Izco S, Migliori GB, et al
    Genotypic and phenotypic M. tuberculosis resistance: guiding clinicians to prescribe the correct regimens.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  59. ABADIE ME, Strich JR, Kim T, Xie YL, et al
    Renal Fanconi syndrome with meropenem/amoxicillin-clavulanate during treatment of extensively drug-resistant tuberculosis.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  60. MIOTTO P, Tessema B, Tagliani E, Chindelevitch L, et al
    A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


    November 2017
  61. LUZZATI R, Migliori GB, Zignol M, Cirillo DM, et al
    Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  62. FALZON D, Migliori GB, Jaramillo E, Weyer K, et al
    Digital health to end tuberculosis in the Sustainable Development Goals era: achievements, evidence and future perspectives.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  63. FURIN J, Lessem E, Cox V
    Recommending prolonged bedaquiline use for the treatment of highly resistant strains of tuberculosis.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  64. KUKSA L, Barkane L, Hittel N, Gupta R, et al
    Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  65. VAN DER WERF MJ, Sotgiu G, Dara M
    Closing the gap in surveillance of tuberculosis and HIV co-infection: a European perspective on the need for clinician-public health alliances.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  66. ARNOLDUSSEN M, Schimmel H, Op de Coul E, van den Hof S, et al
    Tuberculosis patients with unknown HIV status in the Netherlands: analysing underreporting and lack of testing.
    Eur Respir J. 2017;50.
    PubMed     Text format    


    October 2017
  67. VAN DE BERG S, Erkens C, van Rest J, van den Hof S, et al
    Evaluation of tuberculosis screening of immigrants in the Netherlands.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  68. HELDAL E
    A katG 315 mutation alone should not lead to exclusion of isoniazid in treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  69. CHESOV D, Ciobanu N, Lange C, Heyckendorf J, et al
    High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  70. KODAMA C, Lange B, Olaru ID, Khan P, et al
    Mycobacterium tuberculosis transmission from patients with drug-resistant compared to drug-susceptible TB: a systematic review and meta-analysis.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  71. FIEBIG L, Hauer B, Andres M, Haas W, et al
    Tuberculosis screening in asylum seekers in Germany, 2015: characteristics of cases and yield.
    Eur Respir J. 2017;50.
    PubMed     Text format    


    September 2017
  72. FOURNIER A, Bernard C, Sougakoff W, Quelet S, et al
    Neither genotyping nor contact tracing allow correct understanding of multidrug-resistant tuberculosis transmission.
    Eur Respir J. 2017;50.
    PubMed     Text format    


    August 2017
  73. CHEE CBE, KhinMar KW, Sng LH, Jureen R, et al
    The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?
    Eur Respir J. 2017;50.
    PubMed     Text format    


  74. CAZABON D, Suresh A, Oghor C, Qin ZZ, et al
    Implementation of Xpert MTB/RIF in 22 high tuberculosis burden countries: are we making progress?
    Eur Respir J. 2017;50.
    PubMed     Text format    


  75. LEE MR, Ho CM, Lee CH, Lee MC, et al
    Tuberculosis contact investigation in an intermediate burden setting: implications from a large tuberculosis contact cohort in Taiwan.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  76. DOBLER CC, Cheung K, Nguyen J, Martin A, et al
    Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


    July 2017
  77. CAMINERO JA, Piubello A, Scardigli A, Migliori GB, et al
    Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  78. AHMAD KHAN F, Pande T, Tessema B, Song R, et al
    Computer-aided reading of tuberculosis chest radiography: moving the research agenda forward to inform policy.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  79. RAVIGLIONE M, Poznyak V
    Targeting harmful use of alcohol for prevention and treatment of tuberculosis: a call for action.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  80. IMTIAZ S, Shield KD, Roerecke M, Samokhvalov AV, et al
    Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


  81. AHMAD KHAN F, Salim MAH, du Cros P, Casas EC, et al
    Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


  82. ZENNER D, Loutet MG, Harris R, Wilson S, et al
    Evaluating 17 years of latent tuberculosis infection screening in north-west England: a retrospective cohort study of reactivation.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


  83. GUGLIELMETTI L, Varaine F, Huerga H, Bonnet M, et al
    Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance.
    Eur Respir J. 2017;50.
    PubMed     Text format    


  84. ONI T, Berkowitz N, Kubjane M, Goliath R, et al
    Trilateral overlap of tuberculosis, diabetes and HIV-1 in a high-burden African setting: implications for TB control.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


  85. MULLERPATTAN JB, Nikam C, Sharma U, Rodrigues C, et al
    Rifampicin-resistant tuberculosis: what is the best initial empiric regimen in Mumbai, India?
    Eur Respir J. 2017;50.
    PubMed     Text format    


    June 2017
  86. SOLOVIC I, Abubakar I, Sotgiu G, Dara M, et al
    Standard operating procedures for tuberculosis care.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  87. VAN DER WERF MJ, Kodmon C, Catchpole M
    Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  88. HELDAL E, Van Deun A, Chiang CY, Rieder HL, et al
    Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  89. VAN DEUN A, Chiang CY
    Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  90. BOERE TM, Visser DH, van Furth AM, Lips P, et al
    Solar ultraviolet B exposure and global variation in tuberculosis incidence: an ecological analysis.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


    May 2017
  91. OLARU ID, Heyckendorf J, Andres S, Kalsdorf B, et al
    Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  92. GUGLIELMETTI L
    Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity?
    Eur Respir J. 2017;49.
    PubMed     Text format    


  93. MILLER C, Lonnroth K, Sotgiu G, Migliori GB, et al
    The long and winding road of chest radiography for tuberculosis detection.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  94. RAHMAN MT, Codlin AJ, Rahman MM, Nahar A, et al
    An evaluation of automated chest radiography reading software for tuberculosis screening among public- and private-sector patients.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


    April 2017
  95. CATANZARO DG, Trollip AP, Seifert M, Georghiou SB, et al
    Evaluation of the microscopic observation drug susceptibility assay for the detection of first- and second-line drug susceptibility for Mycobacterium tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  96. DALCOLMO M, Gayoso R, Sotgiu G, D'Ambrosio L, et al
    Resistance profile of drugs composing the "shorter" regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  97. NAKIWALA D, Kellgren L, Herzmann C, Olaru ID, et al
    Language discordance between tuberculosis patients and healthcare providers challenging universal access.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  98. BOZORGMEHR K, Joggerst B, Wagner U, Stock C, et al
    Yield of tuberculosis screening in asylum-seekers by country of origin: analysis of screening data in a German federal state (2002-2015).
    Eur Respir J. 2017;49.
    PubMed     Text format    


  99. FALZON D, Jaramillo E, Gilpin C, Weyer K, et al
    Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  100. DAVIES FORSMAN L, Bruchfeld J, Alffenaar JC
    Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    


    March 2017
  101. PONTALI E, D'Ambrosio L, Centis R, Sotgiu G, et al
    Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  102. YASSIN MA, Jaramillo E, Wandwalo E, Falzon D, et al
    Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: to be repeated.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  103. DALCOLMO M, Gayoso R, Sotgiu G, D'Ambrosio L, et al
    Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


  104. FALZON D, Schunemann HJ, Harausz E, Gonzalez-Angulo L, et al
    World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


  105. SINKOU H, Hurevich H, Rusovich V, Zhylevich L, et al
    Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  106. VAN DER WERF MJ, Hollo V, Kodmon C, Dara M, et al
    Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  107. KAMADA A, Amishima M
    QuantiFERON-TB(R) Gold Plus as a potential tuberculosis treatment monitoring tool.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  108. BJORN-MORTENSEN K, Lillebaek T, Koch A, Soborg B, et al
    Extent of transmission captured by contact tracing in a tuberculosis high endemic setting.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  109. VAN KAMPENHOUT E, Bolhuis MS, Alffenaar JC, Oswald LM, et al
    Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  110. UDWADIA ZF, Ganatra S, Mullerpattan JB
    Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  111. GARCIA-BASTEIRO AL, Miranda Ribeiro R, Brew J, Sacoor C, et al
    Tuberculosis on the rise in southern Mozambique (1997-2012).
    Eur Respir J. 2017;49.
    PubMed     Text format    


  112. VAN DER PAARDT AL, Akkerman OW, Gualano G, Palmieri F, et al
    Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  113. LU P, Liu Q, Martinez L, Yang H, et al
    Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  114. ROTH DZ, Ronald LA, Ling D, Chiang LY, et al
    Impact of interferon-gamma release assay on the latent tuberculosis cascade of care: a population-based study.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  115. BASTOS ML, Lan Z, Menzies D
    An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


    February 2017
  116. BLASI F, Matteelli A, Sotgiu G, Cirillo DM, et al
    Moving towards tuberculosis elimination: a call for action from Italy and a possible model for other low tuberculosis incidence countries.
    Eur Respir J. 2017;49.
    PubMed     Text format    


    January 2017
  117. SOTGIU G, Migliori GB
    Group 5 drugs for multidrug-resistant tuberculosis: is the glass half full or half empty?
    Eur Respir J. 2017;49.
    PubMed     Text format    


  118. JAVAID A, Ahmad N, Khan AH, Shaheen Z, et al
    Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  119. FOX GJ, Benedetti A, Cox H, Koh WJ, et al
    Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available


  120. IZCO S, Eyene J, Perez-Lago L, Herranz M, et al
    Equatorial Guinea, a multidrug-resistant tuberculosis hotspot in Central Africa.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  121. FRANCISCO J, Oliveira O, Felgueiras O, Gaio AR, et al
    How much is too much alcohol in tuberculosis?
    Eur Respir J. 2017;49.
    PubMed     Text format    


  122. NATHAVITHARANA RR, Cudahy PG, Schumacher SG, Steingart KR, et al
    Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis.
    Eur Respir J. 2017;49.
    PubMed     Text format     Abstract available



  123. "Monitoring latent tuberculosis infection diagnosis and management in the Netherlands." Connie G.M. Erkens, Erika Slump, Maurits Verhagen, Henrieke Schimmel, Gerard de Vries, Frank Cobelens and Susan van den Hof. Eur Respir J 2016; 47: 1492-1501.
    Eur Respir J. 2017;49.
    PubMed     Text format    


  124. LIENHARDT C, Nahid P, Rich ML, Bansbach C, et al
    Target regimen profiles for treatment of tuberculosis: a WHO document.
    Eur Respir J. 2017;49.
    PubMed     Text format    


    December 2016
  125. PEDRAZZOLI D, Lalli M, Boccia D, Houben R, et al
    Can tuberculosis patients in resource-constrained settings afford chest radiography?
    Eur Respir J. 2016 Dec 23. pii: 1601877. doi: 10.1183/13993003.01877-2016.
    PubMed     Text format    


  126. GUGLIELMETTI L, Jaspard M, Le Du D, Lachatre M, et al
    Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.
    Eur Respir J. 2016 Dec 22. pii: 1601799. doi: 10.1183/13993003.01799-2016.
    PubMed     Text format     Abstract available


  127. VEZIRIS N, Bernard C, Guglielmetti L, Le Du D, et al
    Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors.
    Eur Respir J. 2016 Dec 22. pii: 1601719. doi: 10.1183/13993003.01719-2016.
    PubMed     Text format    


    November 2016
  128. PETRUCCIOLI E, Scriba TJ, Petrone L, Hatherill M, et al
    Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis.
    Eur Respir J. 2016 Nov 11. pii: ERJ-01012-2016. doi: 10.1183/13993003.01012-2016
    PubMed     Text format     Abstract available


  129. ALBERT H, Nathavitharana RR, Denkinger CM, Isaacs C, et al
    Tuberculosis prevention must integrate technological and basic care innovation.
    Eur Respir J. 2016;48:1531-1532.
    PubMed     Text format    


  130. MASON PH, Oni T, van Herpen MM, Coussens AK, et al
    Tuberculosis prevention must integrate technological and basic care innovation.
    Eur Respir J. 2016;48:1529-1531.
    PubMed     Text format    


  131. TADOLINI M, Lingtsang RD, Tiberi S, Enwerem M, et al
    Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
    Eur Respir J. 2016;48:1527-1529.
    PubMed     Text format    


  132. WALLIS RS
    Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
    Eur Respir J. 2016;48:1526-1527.
    PubMed     Text format    


  133. PILARSKI A, Penn N, Ratnakumar S, Barker RD, et al
    Variation in vitamin D deficiency among tuberculosis patients by ethnic group and geographical region of birth: evidence from a diverse south London population.
    Eur Respir J. 2016;48:1507-1510.
    PubMed     Text format    


  134. ERKENS CG, Slump E, Verhagen M, Schimmel H, et al
    Risk of developing tuberculosis disease among persons diagnosed with latent tuberculosis infection in the Netherlands.
    Eur Respir J. 2016;48:1420-1428.
    PubMed     Text format     Abstract available


  135. RENDON A, Fuentes Z, Torres-Duque CA, Granado MD, et al
    Roadmap for tuberculosis elimination in Latin American and Caribbean countries: a strategic alliance.
    Eur Respir J. 2016;48:1282-1287.
    PubMed     Text format    


  136. SOTGIU G, Beer N, Aliberti S, Migliori GB, et al
    Fighting tuberculosis in the EU/EEA: towards the new European Union standards on tuberculosis care.
    Eur Respir J. 2016;48:1278-1281.
    PubMed     Text format    


    October 2016
  137. UPLEKAR M, Atre S, Wells WA, Weil D, et al
    Mandatory tuberculosis case notification in high tuberculosis-incidence countries: policy and practice.
    Eur Respir J. 2016 Oct 20. pii: ERJ-00956-2016. doi: 10.1183/13993003.00956-2016
    PubMed     Text format     Abstract available


  138. VAN ALTENA R, Akkerman OW, Alffenaar JC, Kerstjens HA, et al
    Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly.
    Eur Respir J. 2016 Oct 6. pii: ERJ-01208-2016. doi: 10.1183/13993003.01208-2016.
    PubMed     Text format    


  139. LEE RS, Proulx JF, Menzies D, Behr MA, et al
    Progression to tuberculosis disease increases with multiple exposures.
    Eur Respir J. 2016 Oct 6. pii: ERJ-00893-2016. doi: 10.1183/13993003.00893-2016.
    PubMed     Text format     Abstract available


  140. DE VRIES G, van Rest J, Meijer W, Schimmel H, et al
    Tuberculosis screening yield of asylum seekers in Europe.
    Eur Respir J. 2016;48:1255-1256.
    PubMed     Text format    


  141. ARRAZOLA DE ONATE W, Weber L, Janssens K, Wanlin M, et al
    Tuberculosis screening yield of asylum seekers in Europe.
    Eur Respir J. 2016;48:1253-1254.
    PubMed     Text format    


    September 2016
  142. WINGFIELD T, Tovar MA, Huff D, Boccia D, et al
    The economic effects of supporting tuberculosis-affected households in Peru.
    Eur Respir J. 2016 Sep 22. pii: ERJ-00066-2016. doi: 10.1183/13993003.00066-2016
    PubMed     Text format     Abstract available


    April 2016
  143. TIBERI S, Payen MC, Sotgiu G, D'Ambrosio L, et al
    Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
    Eur Respir J. 2016;47:1235-43.
    PubMed     Text format     Abstract available


    March 2016
  144. KOLAHIAN S, Oz HH, Zhou B, Griessinger CM, et al
    The emerging role of myeloid-derived suppressor cells in lung diseases.
    Eur Respir J. 2016;47:967-77.
    PubMed     Text format     Abstract available


    January 2016
  145. BRIGDEN G, du Cros P, Wong S
    Barriers to new drug development in respiratory disease.
    Eur Respir J. 2016;47:356-7.
    PubMed     Text format    


  146. PINETON DE CHAMBRUN M, Lemiale V, Azoulay E
    Lung positron emission tomography with FDG in patients with haematological malignancies and acute respiratory failure.
    Eur Respir J. 2016;47:324-7.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: